Atara Biotherapeutics, Inc (ATRA) is a publicly traded Healthcare sector company. As of July 27, 2026, ATRA trades at $7.90 with a market cap of $71.18M and a P/E ratio of -10.39. ATRA moved -2.33% today. Year to date, ATRA is -55.82%; over the trailing twelve months it is -35.40%. Its 52-week range spans $3.92 to $19.15. Analyst consensus is buy with an average price target of $13.67. Rallies surfaces ATRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for ATRA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $7.90 |
| Market Cap | $71.18M |
| P/E Ratio | -10.39 |
| EPS | $-0.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.15 |
| 52-Week Low | $3.92 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $23.14M |
| Net Income | $-9.47M |
| Gross Margin | 0.00% |
3 analysts cover ATRA: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.67.